BioLineRx reports results of additional BL-7040 analyses, shares rise

|About: BioLineRx Ltd. (BLRX)|By:, SA News Editor

BioLineRx (BLRX) jumps 7% in premarket trading as the company reports additional results from a Phase 2a study of BL-7040 in IBD.

The company says the new analyses "reinforce the initial positive results of the study" as reported earlier this year.

More specifically, BLRX highlights histological analysis which shows that treated patients saw a significant reduction in neutrophil levels and "also showed a clinical improvement as assessed by their Mayo score." (PR)